Cargando…
Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion
The prognosis of hepatocellular carcinoma (HCC) patients exhibiting macroscopic vascular invasion (MVI) is poor, and the most appropriate treatment approach remains unclear. The current study aimed to investigate the efficacy and safety of sorafenib treatment following chemoradiotherapy for advanced...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776825/ https://www.ncbi.nlm.nih.gov/pubmed/31602300 http://dx.doi.org/10.3892/mco.2019.1920 |
_version_ | 1783456513027735552 |
---|---|
author | Nomura, Takako Tani, Joji Deguchi, Akihiro Nakahara, Mai Oura, Kyoko Tadokoro, Tomoko Fujita, Koji Mimura, Shima Sakamoto, Teppei Morishita, Asahiro Yoneyama, Hirohito Kobara, Hideki Sanomura, Takayuki Nishiyama, Yoshihiro Okano, Keiichi Suzuki, Yasuyuki Takahashi, Shigeo Shibata, Toru Tsutsui, Kunihiko Himoto, Takashi Masaki, Tsutomu |
author_facet | Nomura, Takako Tani, Joji Deguchi, Akihiro Nakahara, Mai Oura, Kyoko Tadokoro, Tomoko Fujita, Koji Mimura, Shima Sakamoto, Teppei Morishita, Asahiro Yoneyama, Hirohito Kobara, Hideki Sanomura, Takayuki Nishiyama, Yoshihiro Okano, Keiichi Suzuki, Yasuyuki Takahashi, Shigeo Shibata, Toru Tsutsui, Kunihiko Himoto, Takashi Masaki, Tsutomu |
author_sort | Nomura, Takako |
collection | PubMed |
description | The prognosis of hepatocellular carcinoma (HCC) patients exhibiting macroscopic vascular invasion (MVI) is poor, and the most appropriate treatment approach remains unclear. The current study aimed to investigate the efficacy and safety of sorafenib treatment following chemoradiotherapy for advanced HCC exhibiting MVI. A newly reported regimen, including 5-fluorouracil and cisplatin therapy (NewFP), plus three-dimensional conformal radiotherapy (3D-CRT) for MVI was used as the initial treatment. Additionally, sorafenib, as a secondary treatment, was administered after NewFP plus 3D-CRT for MVI. The present retrospective study enrolled patients with unresectable advanced HCC that was treated with NewFP plus 3D-CRT for MVI between January 2009 and December 2017. In total, 32 HCC patients with MVI were registered. Of these 32 patients, 18 were treated with NewFP plus 3D-CRT for MVI (NewFP + 3D-CRT group) and 14 were treated with sorafenib following NewFP plus 3D-CRT for MVI (sorafenib after NewFP + 3D-CRT group). The study endpoints were overall survival, overall response rate and disease control rate. Clinical factors influencing overall survival were identified using univariate and multivariate analyses. The median survival time in the NewFP + 3D-CRT group and sorafenib following NewFP + 3D-CRT group was 6.7 and 49.2 months, respectively (P=0.0003). For patients with advanced HCC exhibiting MVI, the initial treatment with NewFP plus 3D-CRT for MVI was well tolerated. The administration of sorafenib as the secondary treatment following NewFP plus 3D-CRT for MVI was associated with a significantly higher overall response rate, disease control rate and increased overall survival as compared with the NewFP plus 3D-CRT treatment. |
format | Online Article Text |
id | pubmed-6776825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-67768252019-10-10 Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion Nomura, Takako Tani, Joji Deguchi, Akihiro Nakahara, Mai Oura, Kyoko Tadokoro, Tomoko Fujita, Koji Mimura, Shima Sakamoto, Teppei Morishita, Asahiro Yoneyama, Hirohito Kobara, Hideki Sanomura, Takayuki Nishiyama, Yoshihiro Okano, Keiichi Suzuki, Yasuyuki Takahashi, Shigeo Shibata, Toru Tsutsui, Kunihiko Himoto, Takashi Masaki, Tsutomu Mol Clin Oncol Articles The prognosis of hepatocellular carcinoma (HCC) patients exhibiting macroscopic vascular invasion (MVI) is poor, and the most appropriate treatment approach remains unclear. The current study aimed to investigate the efficacy and safety of sorafenib treatment following chemoradiotherapy for advanced HCC exhibiting MVI. A newly reported regimen, including 5-fluorouracil and cisplatin therapy (NewFP), plus three-dimensional conformal radiotherapy (3D-CRT) for MVI was used as the initial treatment. Additionally, sorafenib, as a secondary treatment, was administered after NewFP plus 3D-CRT for MVI. The present retrospective study enrolled patients with unresectable advanced HCC that was treated with NewFP plus 3D-CRT for MVI between January 2009 and December 2017. In total, 32 HCC patients with MVI were registered. Of these 32 patients, 18 were treated with NewFP plus 3D-CRT for MVI (NewFP + 3D-CRT group) and 14 were treated with sorafenib following NewFP plus 3D-CRT for MVI (sorafenib after NewFP + 3D-CRT group). The study endpoints were overall survival, overall response rate and disease control rate. Clinical factors influencing overall survival were identified using univariate and multivariate analyses. The median survival time in the NewFP + 3D-CRT group and sorafenib following NewFP + 3D-CRT group was 6.7 and 49.2 months, respectively (P=0.0003). For patients with advanced HCC exhibiting MVI, the initial treatment with NewFP plus 3D-CRT for MVI was well tolerated. The administration of sorafenib as the secondary treatment following NewFP plus 3D-CRT for MVI was associated with a significantly higher overall response rate, disease control rate and increased overall survival as compared with the NewFP plus 3D-CRT treatment. D.A. Spandidos 2019-11 2019-09-09 /pmc/articles/PMC6776825/ /pubmed/31602300 http://dx.doi.org/10.3892/mco.2019.1920 Text en Copyright: © Nomura et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Nomura, Takako Tani, Joji Deguchi, Akihiro Nakahara, Mai Oura, Kyoko Tadokoro, Tomoko Fujita, Koji Mimura, Shima Sakamoto, Teppei Morishita, Asahiro Yoneyama, Hirohito Kobara, Hideki Sanomura, Takayuki Nishiyama, Yoshihiro Okano, Keiichi Suzuki, Yasuyuki Takahashi, Shigeo Shibata, Toru Tsutsui, Kunihiko Himoto, Takashi Masaki, Tsutomu Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
title | Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
title_full | Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
title_fullStr | Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
title_full_unstemmed | Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
title_short | Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
title_sort | efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776825/ https://www.ncbi.nlm.nih.gov/pubmed/31602300 http://dx.doi.org/10.3892/mco.2019.1920 |
work_keys_str_mv | AT nomuratakako efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT tanijoji efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT deguchiakihiro efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT nakaharamai efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT ourakyoko efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT tadokorotomoko efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT fujitakoji efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT mimurashima efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT sakamototeppei efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT morishitaasahiro efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT yoneyamahirohito efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT kobarahideki efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT sanomuratakayuki efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT nishiyamayoshihiro efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT okanokeiichi efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT suzukiyasuyuki efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT takahashishigeo efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT shibatatoru efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT tsutsuikunihiko efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT himototakashi efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion AT masakitsutomu efficacyofcombinedmodalitytherapywithsorafenibfollowinghepaticarterialinjectionchemotherapyandthreedimensionalconformalradiotherapyforadvancedhepatocellularcarcinomawithmajorvascularinvasion |